ATOSSA THERAPEUTICS, INC. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share
ATOSSA THERAPEUTICS, INC. (ATOS) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share of $0.00 per share for the 3-month period ending 2016-09-30, per its 10-Q filed 2016-11-14.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare · last filed 2017-03-21
- ATOSSA THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2016-09-30 was $0.00.
- ATOSSA THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2016-03-31 was $0.00.
- ATOSSA THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2015-09-30 was -$0.30.
- ATOSSA THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2015-03-31 was $0.00.
- ATOSSA THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2015 was -$1.58.
- ATOSSA THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2014 was -$0.10.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 12 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 12 month as first filed |
|---|---|---|---|---|
| 2016-09-30 | $0.00 10-Q · filed 2016-11-14 | $0.00 10-Q · filed 2016-11-14 | ||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-05 | |||
| 2015-12-31 | -$1.58 10-K/A · filed 2017-03-21 | -$0.10 10-K · filed 2016-03-30 | ||
| 2015-09-30 | -$0.30 10-Q/A · filed 2017-03-21 | -$0.37 10-Q/A · filed 2017-03-21 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | -$0.10 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |